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ORIGINAL ARTICLE
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ABSTRACT
Drug-influenced gingival enlargement (DIGE) among hypertensive patients is commonly associated with
antihypertensive drugs such as calcium channel blockers (CCBs). Immune response alteration is one of the
proposed mechanisms for DIGE. Immunoglobulin A (IgA) in saliva which involves in defense mechanism was
shown to be affected in patients with DIGE. Objective: This study aimed to determine the association of salivary
IgA level with DIGE. Methods: This cross-sectional study comprised 47 hypertensive patients who had consumed
antihypertensive drugs for at least 3 months. Twenty-one (44.7%) males and 26 (55.3%) females had participated in
this study. Data was analyzed using SPSS version 26.0. The p-value of less than 0.05 at a 95% confidence interval
is considered statistically significant. Results: Eighty-three percent and 17.0% of hypertensive patients were on
CCBs and non- CCBs respectively. Amlodipine was found to be the most common (55.3%) antihypertensive drug
consumed. Twenty- one (44.7%) patients presented with DIGE. The salivary IgA level was significantly decreased
(p=0.03) among hypertensive patients with DIGE [Median 4.9 ng/mL (IQR 5.268)] compared to those without DIGE
[median 15.03 ng/mL (IQR 32.246)]. Conclusion: This data indicates the level of salivary IgA was significantly
affected in patients with DIGE which may compromise the defense mechanism of saliva.
Key words: drug-influenced, gingival enlargement, calcium channel blocker, salivary IgA, anti-hypertensive drugs
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INTRODUCTION
Hypertension is one of the most prevalent disorders
worldwide; in which by year 2025, approximately 1.56
billion people will suffer from the disease.1,2 Druginfluenced gingival enlargement (DIGE) is commonly
associated with adverse effects of antihypertensive
drugs. This unwanted effect is frequently influenced
by calcium channel blockers such as nifedipine and
amlodipine.3 The clinical features of DIGE include
disfiguration of the gingiva usually affecting interdental
papilla region which results in lobulated or nodular
morphology. If not treated, the condition may lead to
further deterioration of existing periodontal disease
which includes attachment loss or tooth mobility.4,5

The aetiology of DIGE is not completely understood
but it is thought to be multifactorial.6 The underlying
pathogenesis of DIGE involves non-inflammatory and
inflammatory pathways.3,7 In the non-inflammatory
pathway, it is hypothesized that the decrease in
cation inf lux of folic acid active transport within
gingival fibroblasts leads to decreased cellular folate
uptake, which in turn leads to changes in matrix
metalloproteinases metabolism and failure to activate
collagenase. Decreased availability of activated
collagenase results in decreased degradation of
accumulated connective tissue which presents as
gingival enlargement.3
30
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humoral immune response to regulate caries activity
but also interferes with the formation of caries causing
microbial adhesion to the tooth surface and biofilm.15
It has been hypothesized that drug-influenced gingival
enlargement altered the mechanisms of the host’s
immune response causing an increase in gingival
volume and its chronic use lead to a reduction in serum
and salivary IgA, subsequently causing inflammation
of the periodontal tissues.16

Influencing drugs act as a trigger for the activation and
proliferation of gingival fibroblasts, causing an increase
in connective tissue production of glycosaminoglycans.
These dr ugs decrease cellular uptake of folate
by genetically predispose fibroblasts. Reduced
intracellular folate translates into a decrease in the
synthesis or activation of matrix metalloproteinases,
which are required to convert inactive collagenase to
active collagenase, allowing an excess of connective
tissue buildup.8 Moreover, more than 20 enzymes
were found to be involved in the degradation of
connective tissue and tissue remodeling. These
enzymes include collagenases, gelatinases, and
stromelysins. Inhibition of activation of these enzymes
results in the accumulation of extracellular matrix and
collagen and subsequently causing DIGE.8

Decrease in salivary IgA levels was accounted for the
cause of gingival enlargement induced by phenytoin
as well as alteration of subgingival microflora.17,18 This
suggests that the phenytoin drug could be the cause for
terminal differentiation failure of IgA bearing cells.19
However, limited data has been reported on immune
changes in the patient taking calcium channel blockers
(CCBs) influenced gingival enlargement. Therefore,
the current study aimed to determine the association
of salivary IgA level with the presence of DIGE. This
relationship could provide additional information
regarding s-IgA level in hypertensive patients and
understanding its association with the mechanism of
DIGE particularly in patients taking CCBs.

Additionally, the inhibitory effect of sodium or
calcium ion influx upon cation channels mechanisms
and defective collagen. It is also hypothesized that the
pathogenesis of DIGE involved the alteration in sodium
and calcium metabolism at the cellular level in the
non-inflammatory pathway.9 The influx of calcium ion
across the cell membrane is thought to be reduced as
membrane permeability decreases. With the decreased
influx of calcium and sodium, the secretory function of
the affected fibroblastic cells or collagenase production
is also reduced or inhibited, resulting in an increase
fibroblastic proliferation and collagen synthesis.9,10

METHODS
This is a cross-sectional study which was conducted
at the Medical Specialist Clinic and Dental Clinic,
Hospital Universiti Sains Malaysia, Kelantan, Malaysia
involving 47 hypertensive patients. Patients were
selected by convenient sampling on a voluntary basis.
All hypertensive patients aged 18 years old who were
on regular doses of antihypertensive drugs for a
minimum of 3 months prior to the study were included.
Exclusion criteria include edentulism, pregnant mother,
patients who had undergone periodontal treatment
within 6 months prior to the study, patients who were
on medications known to cause gingival enlargement
such as phenytoin or having systemic disorders which
known to affect the gingiva such as leukemia.

On the other hand, the inflammatory pathways include
alteration in the production of inflammatory cytokines
and interaction of chemotactic factors; immunity
changes as well as inf lammatory process. 3,11 The
concentrated drug in crevicular gingival fluid or bacterial
plaque exerts a direct toxic effect on the gingival tissue.
Dental plaque induces inflammation, subsequently
causing gingival enlargement. Inflammation enhances
the upregulation of transforming growth factor-beta
1 (TGF-β1) which is known to have an essential
role in cell proliferation associated with DIGE.8,12
Additionally, inflamed gingival tissue also exhibits
higher levels interleukin-1 beta (IL-1β).8 IL-1β is a
pro-inflammatory multifunctional cytokine which is
produced in large amounts by macrophage monocytes
and plays a significant role in periodontal disease.
The inflamed gingival tissue is due to an increase
in capillary wall permeability stimulated by this
cytokine.13 Moreover, interleukin-6 (IL-6) enhances
fibroblastic proliferation and increased the production
of collagen and glycosaminoglycans synthesis leading
to gingival enlargement.8

All patients were briefed regarding the study procedures
and informed written consents were obtained. The
demographic data, medical history, drug history
were retrieved from medical record and oral clinical
examination was performed.
Saliva collection
About 1.5 milliliters of unstimulated whole saliva
samples were collected from all patients. The saliva
samples were collected on one occasion under resting
conditions during morning hours, between 9am to
12noon after cleaning their mouth. Patients were
requested to keep their mouth closed for 5 minutes in
order to pool the saliva, then spitted into a container.
The saliva samples then were immediately sent to
the laboratory and frozen at -80°C before analysis.
Hypertensive patients who presented with DIGE,

Immunoglobulin A (IgA) is the most abundant antibody
isotype in the body, comprising almost 70 percent
of the body’s total immunoglobulin. IgA is found
mostly in mucosal secretions including saliva, milk,
colostrum, tears, secretions from the respiratory tract,
genitourinary tract, as well as prostate.14 Salivary
immunoglobulin A (s-IgA) not only mediates the
31
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periodontal disease or other dental problems were
referred for further treatment. This study protocol
was approved by Human Research Ethics Committee
USM(USM/JEPeM/18090407).

Table 1. Demographic characteristic of the study subjects
(n=47)

Salivary IgA measurement
The s-IgA levels were determined using a commercial
kit of Enzyme-linked Immunosorbent Assay (ELISA)
test for IgA: Homo sapiens (Human) (Cloud-Clone
Corporations, USA). The microplate provided has
been pre-coated with an antibody specific to IgA.
The samples were prepared in triplicates to avoid
any inconsistency or variation of the test. Standard
or samples were added into appropriate microplate
wells with a biotin-conjugated antibody specific to
IgA. Avidin conjugated to Horseradish Peroxidase
(HRP) was added into each microplate well and
incubated. After Thio- Methylene Blue substrate
solution was added, only those wells that contain IgA,
biotin-conjugated antibody and enzyme-conjugated
Avidin showed a change in colour. The enzymesubstrate reaction was terminated by the addition of
sulphuric acid solution. The colour change was equal
to the concentration of IgA in the sample. The s- IgA
concentration was measured spectrophotometrically at
the wavelength of 450 ± 10nm. The IgA concentration
of more than 0.07ng/mL was considered positive.

Variables

Frequency,
n (%)

Age, years (Mean ± SD)

(55.7 ±
SD 10.0)

Gender
Male
Female

21 (44.7)
26 (55.3)

Ethnicity
Malay
Chinese

46 (97.9)
1 (2.1)

Duration on HPT medication (years)
< 5 years
5 – 10 years
> 10 years

14 (29.8)
22 (46.8)
11 (23.4)

Types of antihypertensive
a
CCB
Non-CCB

39 (83.0)
8 (17.0)

Other systemic diseases
Yes
No

28 (59.6)
19 (40.4)

Drug influenced gingival enlargement
Presence
Absence

21 (44.7)
26 (55.3)

HPT = hypertension;
CCB = calcium channel blockers, a55.3% Amlodipine
Table 2. Comparison of salivary IgA levels in hypertensive
patients with and without gingival enlargement (n= 47)

Data Analysis
Data were analyzed by using the Statistical Package
for the Social Sciences (SPSS) version 26.0. Data
checking and cleaning were performed before analysis.
Descriptive analysis were presented as mean (SD)
or median (interquartile range, IQR) for continuous
variables, and frequency and percentage (%) for
categorical variables. Mann-Whitney U test was used
to compare the levels of s-IgA in hypertensive patients
with and without DIGE. The p-value of <0.05 at 95%
confidence interval (CI) was considered statistically
significant.

Variable

DIGE
group
n=21
Median
(IQR)

Salivary
IgA level
(ng/mL)

4.90
(5.268)

NonDIGE
group
n= 26
Median
(IQR)
15.03
(32.246)

Z statistica

p

173.500

0.033

Mann-Whitney U Test; b Significant value was set at
p<0.05 DIGE=Drug-Inf luenced Gingival Enlargement
IQR=Interquartile Range
a

RESULTS
Forty-seven hypertensive patients with a mean age of
55.7 ± 10.0 years were included in this study. Majority
of them were Malays (97.6%) comprised of 21 (44.7%)
males and 26 (55.3%) females. Seventy percent of
patients had consumed antihypertensive drugs for more
than 5 years. Amlodipine was the commonest drug
consumed (55.3%) followed by felodipine (25.5%) and
nifedipine (2.1%). More than half (59.6%) of patients
had other systemic diseases such as diabetes mellitus,
dyslipidemia, ischemic heart disease, and lung disease
which were under control and on regular follow up
(Table 1).

was not normally distributed based on Shapiro-Wilk
Normality Test (p=0.001). Hence, the non-parametric
test, Mann-Whitney U Test was employed. The level
of s-IgA is expressed in median and interquartile
range (IQR). The mean s-IgA levels in DIGE group
was significantly low (4.90 ± 5.27 ng/mL) compared to
non-DIGE group (15.03 ± 32.25 ng/mL), with p= 0.033.

DISCUSSION
The precise mechanism by which DIGE occurs is
not completely understood, although a number of
hypotheses have been suggested. 20 Three classes
of drugs which are well-known to cause gingival
enlargement in most cases, namely antihypertensive

Almost half of the patients (44.7%) presented with
DIGE. Table 2 shows the comparison of the s-IgA
levels between patients with and without GE. The data
32
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drugs such as CCBs, immunosuppressant cyclosporine
and anti-convulsant drug such as phenytoin.20 Druginfluenced gingival enlargement was first observed
in patients taking phenytoin for epilepsy, with
approximately 50.0% having gingival overgrowth.
Cyclosporin is an immunosuppressant which has
been reported to cause gingival enlargement in
25.0 % to 80.0% of patients. Among the CCBs, the
dihydropyridines such as nifedipine, felodipine, and
amlodipine tend to be more commonly associated with
gingival enlargement.21 The particular property that is
common to these classes of drugs is that they directly
affect the cellular calcium metabolism. Since cellular
production of collagenase is modulated by calcium
influx, fibroblasts from patients treated with these
drugs may produce an inactive form of collagenase,
leading to an increase in extracellular matrix deposition
subsequently causing gingival enlargement.20

In this present study, s-IgA is significantly reduced
in hypertensive patients with DIGE (p=0.033). A
decrease in s- IgA antibody level was also reported
by previous studies in patients taking phenytoin. As a
consequence, patients taking this medication may be
at greater risk for acquiring oral microbial infection.29
This finding is supported by another study which
showed s-IgA deficiency in saliva and serum compared
to IgM antibody, however, no statistically difference in
the three types of tissue assayed; control, idiopathic
gingival hyperplastic tissues and phenytoin influenced
gingival enlargement.28
In addition, the adaptive humoral immunity system
at the mucosal surface is mediated by secretory IgA
antibodies.30 On top of that, TGF-β, and interleukin-10
(IL-10) together with interleukin-4 (IL-4) have
been shown to promote B cells to switch to IgA and
differentiate into IgA-producing cells.31 It is believed
that the decrease in salivary IgA in hypertensive
patients with GE could be predominantly influenced
by the diminution of TGF-B. Trackmann et al, reported
that the effect of TGF-β, which has unexpectedly less
magnitude of regulation compared to other connective
tissue cells which were performed under the same
conditions of DIGE.32

The decrease in calcium influx in patients taking CCBs
is due to alterations in calcium-sodium exchange, which
causes a decrease in cellular folic acid uptake, thus,
limiting the production of the collagenase-activating
enzyme. Since the presence of inflammation secondary
to dental plaque causes proliferative increase in
connective tissue, the catabolic ability of collagenase
is saturated, and the inhibited degradation of the extra
cellular matrix causes a local accumulation of this
matrix.20 Meanwhile, the inflammatory changes within
the tissue may enhance the interaction of calcium
and fibroblast cells.10 Oral microbes’ antigens are
continuously being affected by the two major antibody
classes in saliva; salivary IgA and IgG.22 There are two
possible sequences of DIGE events. Firstly, in patients
with existing gingival inf lammation, consuming
antihypertensive medication may further exacerbate
the DIGE.9 It is now well established that gingival
inflammation is an essential cofactor in the expression
of DIGE.23 Secondly, there are occasions where patient
with no existing gingival inflammation revealed DIGE
after taking antihypertensive drugs. However, there
are several studies that could not determine the true
sequence of events with respect to the role of gingival
inflammation in the development of DIGE.24, 25

To understand the less magnitude of TGF-β on
extracellular matrix synthesis in gingival fibroblasts,
the researchers in recent studies have shifted and more
focused on the presence and role of connective tissue
growth factor (CTGF) as a possible matrix stimulatory
factor regardless of TGF-β in gingival enlargement
tissues.32 CTGF has been proposed to mediate the
effects of TGF-β on extracellular matrix metabolism.33
Therefore, it can be proposed that the decrease in s-IgA
levels among hypertensive patients with GE could be
due to the effect of less magnitude TGF-β regulation,
subsequently leads to reduce function of B cells in
class-switching of IgA to IgA producing cells.
This study faced several limitations. First, the small
sample size in this study was not enough to represent
the entire antihypertensive drug-inf luenced GE
population, so our findings cannot be generalized
to any other groups. Another limitation was that the
saliva samples were only collected after exposure
of the antihypertensive drugs with various duration
of the treatment. Hence, we could not identify the
difference on each subject before and after exposure
of antihypertensive drugs. We recommend to include
larger sample size in future study to obtain more
convincing findings. In addition, it is essential to
determine the exact role of s-IgA in the pathogenesis
of drug influenced gingival enlargement. CTGF and
TGF-β also could be investigated and correlate with the
quantification of s-IgA since both cytokines may have
an effect towards the decrease in s-IgA level.

The secretory immune system is referring to a complex
regulation of immune cells in which it influences
distinctly the activity of various cell types involved
in s-IgA formation.26 Genco et al. has reported that
immune complexes are formed during gingival
inflammation.27 They suggested that plaque antigens
entering gingival connective tissue combine with
antibody forming antigen-antibody complexes and
deposited in the tissue; or if they have an affinity for a
tissue component, it will localize in this component.27
These antigen-antibody complexes were believed to
enhance and block the local cellular immune reactions
in gingiva during periodontal inflammation.28

33
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CONCLUSION
The s-IgA antibody levels were significantly reduced
in hypertensive patients with DIGE which may
compromise the defense mechanism of saliva.
However, the s-IgA does not exclusively regulate
the pathway of DIGE but could be served as a future
potential biomarker in assessing gingival enlargement
in hypertensive patients.
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